ESG3 Sept 2026, 02:29 pm
Piramal Pharma ESG Rating Improves to 65 for FY25-26
AI Summary
Piramal Pharma Ltd has received an ESG Rating of 65 for FY 2025-26 from NSE Sustainability Ratings and Analytics Limited. This rating marks an improvement from the previous score of 64, reflecting the company's sustained commitment to environmental, social, and governance principles. Notably, NSE Sustainability independently assigned this rating based on publicly available data, without any prior engagement with Piramal Pharma. The company has also made this information available on its website.
Key Highlights
- Piramal Pharma's ESG rating improved to 65 for FY25-26.
- The rating was assigned by NSE Sustainability Ratings and Analytics.
- The company was not engaged for this voluntary ESG assessment.
- The improved score reflects ongoing commitment to sustainability.
- Rating is based on publicly available data for FY25-26.
Price Impact
More from PPLPHARMA